The Phase 3 NETTER-1 Study of [Lu-177]Lu-DOTA-TATE in Patients with Midgut Neuroendocrine Tumours: Final Overall Survival and Long-Term Renal Safety

Kunz P, Caplin ME, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Demange A, Mutevelic S, Strosberg JR, Krenning EP (2021)


Publication Type: Conference contribution

Publication year: 2021

Journal

Publisher: SPRINGER

City/Town: NEW YORK

Pages Range: S188-S188

Conference Proceedings Title: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Kunz, P., Caplin, M.E., Ruszniewski, P.B., Bodei, L., Hendifar, A., Mittra, E.,... Krenning, E.P. (2021). The Phase 3 NETTER-1 Study of [Lu-177]Lu-DOTA-TATE in Patients with Midgut Neuroendocrine Tumours: Final Overall Survival and Long-Term Renal Safety. In EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (pp. S188-S188). NEW YORK: SPRINGER.

MLA:

Kunz, P., et al. "The Phase 3 NETTER-1 Study of [Lu-177]Lu-DOTA-TATE in Patients with Midgut Neuroendocrine Tumours: Final Overall Survival and Long-Term Renal Safety." Proceedings of the EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING NEW YORK: SPRINGER, 2021. S188-S188.

BibTeX: Download